A
Report of the Committee to Review the Adverse Consequences of
Pertussis and Rubella Vaccines
Division of Health
Promotion and Disease Prevention
Institute of
Medicine
NATIONAL ACADEMY PRESS
Washington, D.C. 1991
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page R1
Adverse Effects of Pertussis and Rubella
Vaccines
A
Report of the Committee to Review the Adverse Consequences of
Pertussis and Rubella Vaccines
Christopher P. Howson, Cynthia J. Howe,
and Harvey V. Fineberg, Editors
Division of Health
Promotion and Disease Prevention
Institute of
Medicine
NATIONAL ACADEMY PRESS
Washington, D.C. 1991
OCR for page R1
Page ii
NATIONAL ACADEMY PRESS · 2101 Constitution Avenue,
N.W. • Washington, D.C. 20418
NOTICE: The project that is the subject of this report was
approved by the Governing Board of the National Research Council,
whose members are drawn from the councils of the National Academy
of Sciences, the National Academy of Engineering, and the Institute
of Medicine. The members of the committee responsible for the
report were chosen for their special competences and with regard
for appropriate balance.
This report has been reviewed by a group other than the authors
according to procedures approved by a Report Review Committee
consisting of members of the National Academy of Sciences, the
National Academy of Engineering, and the Institute of Medicine.
The Institute of Medicine was chartered in 1970 by the National
Academy of Sciences to enlist distinguished members of the
appropriate professions in the examination of policy matters
pertaining to the health of the public. In this the Institute acts
under the Academy's 1863 congressional charter responsibility to be
an adviser to the federal government and, upon its own initiative,
to identify issues of medical care, research, and education. Dr.
Samuel O. Thier is President of the Institute of Medicine.
The project was supported by funds coordinated through the
National Institute of Allergy and Infectious Diseases of the
National Institutes of Health (contract no. NOI-AI-95041).
Library of Congress Cataloging-in-Publication Data
Institute of Medicine (U.S.). Committee to Review the Adverse
Consequences of Pertussis and Rubella Vaccines.
Adverse effects of pertussis and rubella vaccines : a report of
the
Committee to Review the Adverse Consequences of Pertussis and
Rubella Vaccines / Christopher P. Howson, Cynthia J. Howe,
and
Harvey V. Fineberg, editors.
p. cm.
Includes bibliographical references and index.
ISBN 0-309-04499-5
1. Pertussis vaccinesSide effectsCongresses. 2.
Rubella
vaccines-Side effectsCongresses. 3. Whooping
coughPreventive
inoculationComplications and sequelaeCongresses. 4.
Rubella
Preventive inoculationComplications and
sequelaeCongresses.
I. Howson, Christopher Paul. II. Howe, Cynthia J. III.
Fineberg,
Harvey V. IV. Title.
[DNLM: 1. Pertussis Vaccineadverse effects. 2. Rubella
Vaccine
adverse effects. WC 340 159r]
QR 189.5.P46156 1991
615'.372dc20
DNLM/DLC
for Library of Congress
91-25665
CIP
Copyright © 1991 by the National Academy of
Sciences
No part of this book may be reproduced by any mechanical,
photographic, or electronic procedure, or in the form of a
phonographic recording, nor may it be stored in a retrieval system,
transmitted, or otherwise copied for public or private use, without
written permission from the publisher, except for the purpose of
official use by the United States government.
Printed in the United States of America
The serpent has been a symbol of long life, healing, and
knowledge among almost all cultures and religions since the
beginning of recorded history. The image adopted as a logotype by
the Institute of Medicine is based on a relief carving from ancient
Greece, now held by the Staatlichemusseen in Berlin.
OCR for page R1
Page iii
COMMITTEE TO REVIEW THE ADVERSE CONSEQUENCES OF PERTUSSIS AND
RUBELLA VACCINES
HARVEY V. FINEBERG (Chairman), Dean, Harvard School of
Public Health, Boston, Massachusetts
JOHN C. BAILEY, Director, Bear River District Health Department,
Logan, Utah
MARY LUZ COADY, Director, Department of Pediatrics, Bryn Mawr
Hospital, Bryn Mawr, Pennsylvania
LINDA D. COWAN, Associate Professor, Department of Biostatistics
and Epidemiology, College of Public Health, University of Oklahoma,
Oklahoma City, Oklahoma
MARIE R. GRIFFIN, Associate Professor, Department of Preventive
Medicine, Vanderbilt University Medical Center, Nashville,
Tennessee
RICHARD B. JOHNSTON, JR., William H. Bennett Professor of
Pediatrics, University of Pennsylvania School of Medicine, and
Childrens' Hospital of Philadelphia, Philadelphia, Pennsylvania
MICHAEL KATZ, Reuben S. Carpentier Professor and Chairman,
Department of Pediatrics, College of Physicians and Surgeons, and
Professor of Public Health (Tropical Medicine), School of Public
Health, Columbia University, New York, New York
DARWIN R. LABARTHE, James W. Rockwell Professor of Public
Health, School of Public Health, The University of Texas Health
Science Center at Houston, Houston, Texas
DAVID A. LANE, Professor, Department of Theoretical Statistics,
University of Minnesota, Minneapolis, Minnesota
FREDERICK MOSTELLER, Roger I. Lee Professor of Mathematical
Statistics, Emeritus, Director, Technology Assessment Program,
Harvard University, Boston, Massachusetts
BENNETT A. SHAYWITZ, Professor of Pediatrics, Neurology, &
Child Study Center, Yale University School of Medicine, New Haven,
Connecticut
Project Staff
CHRISTOPHER P. HOWSON, Project Director
CYNTHIA J. HOWE, Program Officer
DOROTHY R. MAJEWSKI, Project Assistant
MICHAEL A. STOTO, Senior Program Officer
CYNTHIA H. ABEL, Financial Associate
MICHAEL K. HAYES, Contract Editor
OCR for page R1
Page iv
Institute of Medicine
SAMUEL O. THIER, President
ENRIQUETA C. BOND, Executive Officer
GARY B. ELLIS, Director, Division of Health Promotion and
Disease Prevention
OCR for page R1
Page v
Preface
Although vaccines have markedly reduced the toll of many
childhood illnesses, the practice of vaccination is not always
without risk. Minor side effects are common, and serious side
effects, although less numerous, have been observed on rare
occasions with certain vaccines. Whether there are increased risks
of serious adverse events following whole-cell pertussis and
rubella vaccines, however, is controversial. The fact that
pertussis and rubella vaccination is mandatory in many states has
heightened public awareness of controversy and concern about the
safety of the two vaccines.
In response to concerns about possible adverse consequences of
legally mandated vaccines, the U.S. Congress in 1986 passed the
National Childhood Vaccine Injury Act (Public Law 99-660), followed
by the Vaccine Compensation Amendments of 1987 (Public Law
100-203). The core of the legislation was the establishment of a
federal compensation scheme for persons potentially injured by
vaccines, to be funded by excise taxes imposed on manufacturers of
vaccines. In addition, Section 312 of Public Law 99-660 also called
for a review of scientific and other information on possible
adverse consequences of the pertussis and rubella vaccines. The
Institute of Medicine (IOM) was specifically asked to conduct this
review, and funds coordinated by the National Institute of Allergy
and Infectious Diseases were made available for this purpose in
September 1989.
In November 1989, IOM established the Committee to Review the
Adverse Consequences of Pertussis and Rubella Vaccines. The
specific charge
OCR for page R1
Page vi
to the committee, as outlined in Section 312 of the National
Childhood Vaccine Injury Act, was to:
· identify and review all
available medical and scientific literature on the nature,
circumstance, and extent of the relationship, if any, between
vaccines containing pertussis (including whole cells, extracts, and
specific antigens) and the following illnesses and conditions:
hemolytic anemia, hypsarrhythmia, infantile spasms, Reye syndrome,
peripheral mononeuropathy, deaths classified as sudden infant death
syndrome (SIDS), aseptic meningitis, juvenile diabetes, autism,
learning disabilities, hyperactivity, and other such illnesses as
recommended by the committee or the Advisory Commission on
Childhood Vaccines, and inquire into the possible association
between pertussis vaccines and permanent neurologic damage;
· conduct a similar review of
the potential relationship between rubella vaccines (including the
measles-mumps-rubella combination vaccine) and
radiculoneuritis;
· sponsor a workshop on
pertussis and rubella vaccines that shall include invited
researchers and experts on vaccine-related illness and
conditions;
· conduct a public meeting
covering both pertussis and rubella vaccines to obtain information
from a variety of interested parties; and
· prepare a report that
presents the committee's assessment of evidence and conclusions
about the possible association between pertussis and rubella
vaccines and these specific adverse events.
At its first meeting in January 1990, the committee voted to add
chronic arthritis to the list of adverse events to be examined with
respect to rubella vaccines. In May 1990, at the request of the
Advisory Commission on Childhood Vaccines, the committee agreed to
consider seven additional adverse events: anaphylaxis; erythema
multiforme or other rashes; GuillainBarrè syndrome
(polyneuropathy); protracted inconsolable crying or screaming;
thrombocytopenia; and shock and "unusual shock-like state" with
hypotonicity, hyporesponsiveness, and short-lived convulsions
(usually febrile), with respect to pertussis vaccines; and
thrombocytopenic purpura, with respect to rubella vaccines.
The 11-member interdisciplinary committee appointed to conduct
the study included individuals with expertise in infectious
diseases, pediatrics, internal medicine, neurology, epidemiology,
biostatistics, decision analysis, biologic mechanisms of vaccines,
immunology, and public health. During the course of the 20-month
study, the committee examined a wide range of information sources,
including case series and individual case reports published in
peer-reviewed journals and reported by vaccine manufacturers;
unpublished case reports from physicians, parents, and other
concerned persons; epidemiologic studies; studies in animals; and
other laboratory studies. Whenever possible, the committee examined
primary sources of data.
OCR for page R1
Page vii
Other works, for example, the Report of the Task Force on
Pertussis and Pertussis Immunization1988 published in
1988 by the American Academy of Pediatrics, DPT: A Shot in the
Dark published in 1985 by Coulter and Fisher, and the 1985
Institute of Medicine report Vaccine Supply and Innovation
provided secondary sources of information. The committee also
considered a variety of other data sources, including conference
and symposium proceedings, legal judgments, and academic
dissertations. By drawing on a variety of information sources, the
committee has attempted to ensure a comprehensive and critical
review.
The committee held five meetings during which it evaluated the
literature and prepared its general review and summary. A public
meeting convened at the outset of the study served as a forum for
open discussion and presentation of views and information by
individual scientists and by representatives of medical specialty
organizations, parent groups, vaccine manufacturers, and the legal
community.
The committee also conducted one workshop during which it
interacted with and shared the expertise and research findings of a
larger community of scientists representing a range of views on
topics pertinent to the committee's charge. The workshop provided
an opportunity for the committee members to consider new or
controversial data and various points of view and to identify gaps
in knowledge. The subjects considered in the workshop included the
time course of events following pertussis or rubella vaccination,
variations in pertussis and rubella vaccine compositions and their
implications for evaluating possible adverse events following
vaccination, evidence concerning the possible relationship of
pertussis vaccines to irreversible encephalopathy and sudden infant
death syndrome, and evidence concerning any relationship of rubella
vaccines to radiculoneuritis, peripheral neuropathy, and chronic
arthritis.
The committee's report is presented in seven chapters and six
appendixes. The report also includes a glossary of terms and a
bibliography of information sources. Chapter 1 provides an
executive summary of the report. Chapter 2 offers a brief history
of the development of pertussis and rubella vaccines and of the
controversy concerning their possible associations with severe
adverse events. Chapter 3 details the methodologic considerations
of the committee in its evaluation of the evidentiary base.
Chapters 4 through 6 present the evidence pertaining to pertussis
vaccines and specific adverse events, and Chapter 7 presents
evidence pertaining to rubella vaccine and specific adverse events.
An afterword on research needs follows Chapter 7. Appendix A
describes the strategies the committee used to gather its
information. Appendix B provides a brief chronology of pertussis
and rubella vaccines. Appendix C discusses animal models used in
studying pertussis and in the testing of vaccines. Appendix D
describes the technical details of the committee's power
calculations and meta-analyses.
OCR for page R1
Page viii
Appendix E discusses the possible involvement of aluminum salts
in adverse events following pertussis immunization. Appendix F
provides brief biographies of committee members. In preparing its
report, the committee recognized that its charge was to focus on
questions of causation and not broader, although important, topics,
such as cost-benefit or risk-benefit analyses of vaccination.
We hope that this report will provide a
foundation of evidence and methods that may also be useful
to others concerned with assessing the safety of vaccines.
Harvey V. Fineberg, Chairman
Committee to Review the Adverse Consequences of Pertussis and
Rubella Vaccines
OCR for page R1
Page ix
Acknowledgments
The committee wishes to thank the many people who provided
information to the committee, including Kenneth Bart, National
Vaccine Program; Philip Berry, Berry & Berry; Thomas P. Bleck,
Rush Memorial Hospital; Dean A. Blumberg, University of California,
Los Angeles; E. Borst-Eilers, The Health Council of The
Netherlands; James D. Cherry, University of California, Los
Angeles; Richard V. Colan, pediatric neurologist; Harris L.
Coulter, Center for Empirical Medicine; George Curlin, National
Institute of Allergy and Infectious Diseases; Marie Valdes Dapena,
University of Miami; Darryl DeVivo, Neurological Institute; Charles
A. Dinarello, Tufts University School of Medicine; Mr. and Mrs.
Donny Epps, Athens, Georgia; Barbara Loe Fisher, Dissatisfied
Parents Together; Kay A. Fox, Chronic Rubella Viremia Support;
Ronald Gabriel, University of California, Los Angeles; James L.
Gale, University of Washington; Mark Geier, medical/ legal
consultant; Marjorie Grant, Determined Parents to Stop Hurting Our
Tots; Rajesh K. Gupta, Visiting Fellow, National Institute of Child
Health and Human Development; Stephen C. Hadler, Centers for
Disease Control; Joanne M. Hatem, York Gastroenterology; Rosemary
Havill, Health Resources and Services Administration; Carole A.
Heilman, National Institute of Allergy and Infectious Diseases;
Erik L. Hewlett, University of Virginia School of Medicine; Alan R.
Hinman, Centers for Disease Control; Ulla Hoikkala, Embassy of
Finland; Michael R. Hugo, Schlichtmann, Conway, Crowley & Hugo;
David L. Klein, National Institute of Allergy and Infec-
OCR for page R1
Page x
tious Diseases; Daniel Lahn, National Vaccine Program; Leonard
P. Kurland, Mayo Clinic; John R. LaMontagne, National Institute of
Allergy and Infectious Diseases; Stephan Lawton, Reed, Smith, Shaw
& McClay; Charles R. Manclark, Food and Drug Administration;
Cynthia McCormick, Vaccine Injury Compensation Program; David L.
Miller, St. Mary's Hospital Medical School, London; John Mullen,
Centers for Disease Control; J. Anthony Morris, The Bell of Atri,
Inc.; Edward A. Mortimer, Jr., Case Western Reserve University
School of Medicine; Yuth Nimit, National Vaccine Program; Walter A.
Orenstein, Centers for Disease Control; Georges Peter, Rhode Island
Hospital; Stanley A. Plotkin, Pasteur Mèrieux Connaught
Company; Keith Redhead, National Institute for Biological Standards
and Control; Joseph Reini, Embassy of Finland; Noel R. Rose, The
Johns Hopkins School of Hygiene and Public Health; Jeffrey
Schwartz, Jellinek, Schwartz, Connolly & Freshman, Inc.; John
Sladky, Children's Hospital of Philadelphia; Martin Smith,
pediatrician; Mark E. Thoman, Iowa Poison Control Center; Dirk
Teuwen, SmithKline Biologicals; Puru Thapa, University of
Washington; Aubrey Tingle, British Columbia Children's Hospital;
Alexander Walker, Harvard School of Public Health; Steven G.
Wassilak, Centers for Disease Control; Jeanette Wilkins, University
of Southern California School of Medicine; and Arthur C. Zahalsky,
Southern Illinois University.
The committee would also like to thank individuals within the
IOM whose support was instrumental. Leading the list are
Christopher P. Howson, Project Director, and Cynthia J. Howe,
Program Officer, whose hard work and dedication ensured the
completion of the report, and Michael A. Stoto, Senior Program
Officer in the Division of Health Promotion and Disease Prevention,
for invaluable assistance in developing and applying evaluative
methods used in this report. We are grateful, also, to Dorothy R.
Majewski, secretary to the project, who typed volumes, arranged
travel, and assisted at meetings, and to Jane Durch for help with
the graphics. Others within IOM and the National Academy of
Sciences who were instrumental in seeing the project to completion
were Samuel O. Thier, President of IOM; Enriqueta C. Bond,
Executive Officer of IOM; Gary B. Ellis, Director of the Division
of Health Promotion and Disease Prevention; and Sally S. Stanfield
and Francesca T. Moghari, National Academy Press. We appreciate the
editorial assistance of Michael Hayes, Leah Mazade, Betsy Turvene,
and Wallace Waterfall. Finally, this report could not have been
completed without the expert help of National Research Council
librarians Pamela Pangburn, Janet Ewing, Valerie Foster, and
Yauthary Keo and IOM librarian Samuel Johnson.
OCR for page R1
Page xi
Contents
1 Executive Summary
1
2 Histories of Pertussis and Rubella
Vaccines
9
3 Methodologic Considerations in
Evaluating the Evidence
32
4 Evidence Concerning Pertussis Vaccines
and Central Nervous System Disorders, Including Infantile Spasms,
Hypsarrhythmia, Aseptic Meningitis, and Encephalopathy
65
5 Evidence Concerning Pertussis Vaccines
and Deaths Classified as Sudden Infant Death Syndrome (SIDS)
125
6 Evidence Concerning Pertussis Vaccines
and Other Illnesses and Conditions
144
Anaphylaxis
144
Autism
151
Erythema Multiforme or Other Rash
152
Guillain-Barrè Syndrome
(Polyneuropathy)
154
Peripheral Mononeuropathy
156
Hemolytic Anemia
157
Juvenile Diabetes
159
OCR for page R1
Page xii
Learning Disabilities and
Hyperactivity
161
Protracted Inconsolable Crying and
Screaming
165
Reye Syndrome
169
Shock and ''Unusual Shock-Like State"
with Hypotonicity, Hyporesponsiveness, and Short-Lived Convulsions,
Usually Febrile
171
Thrombocytopenia
177
7 Evidence Concerning Rubella Vaccines and
Arthritis, Radiculoneuritis, and Thrombocytopenic Purpura
187
Afterword on Research Needs
206
Bibliography
208
Glossary of Terms
283
Appendixes
A. Strategies for Gathering Information:
Adverse Effects of Pertussis and Rubella Vaccines
293
B. Pertussis and Rubella Vaccines: A Brief
Chronology
320
C. Animal Models for the Study of Whooping
Cough and the Testing of Vaccine Materials
333
D. Technical Details of Power Calculations
and Meta-Analyses
337
E. Possible Involvement of Aluminum Salts
in Erythema Multiforme, Encephalopathy, or Other Adverse Events
After Pertussis Immunization
347
F Committee Biographies
349
Index
355
OCR for page R1
Adverse Effects of
PIRTUSSISon~ RUBBLE
Vaccines
OCR for page R1